Teacher Retirement System of Texas Acquires Shares of 185,143 Acorda Therapeutics Inc (ACOR)

Teacher Retirement System of Texas acquired a new stake in Acorda Therapeutics Inc (NASDAQ:ACOR) in the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 185,143 shares of the biopharmaceutical company’s stock, valued at approximately $2,461,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Texas Permanent School Fund lifted its stake in Acorda Therapeutics by 3.9% in the 1st quarter. Texas Permanent School Fund now owns 26,844 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 1,013 shares during the last quarter. Comerica Bank lifted its stake in Acorda Therapeutics by 2.8% in the 1st quarter. Comerica Bank now owns 39,284 shares of the biopharmaceutical company’s stock valued at $502,000 after purchasing an additional 1,053 shares during the last quarter. Bank of Montreal Can lifted its stake in Acorda Therapeutics by 100.8% in the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,062 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Acorda Therapeutics by 45.8% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,106 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,289 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Acorda Therapeutics by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 327,281 shares of the biopharmaceutical company’s stock valued at $5,099,000 after purchasing an additional 1,841 shares during the last quarter.

ACOR stock traded up $0.35 during mid-day trading on Tuesday, hitting $11.11. 11,293 shares of the company were exchanged, compared to its average volume of 880,615. The company has a quick ratio of 3.97, a current ratio of 4.30 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $524.14 million, a PE ratio of 6.12 and a beta of 1.34. Acorda Therapeutics Inc has a 1-year low of $9.58 and a 1-year high of $36.35.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.51. The firm had revenue of $44.14 million during the quarter, compared to the consensus estimate of $35.14 million. Acorda Therapeutics had a negative net margin of 1.40% and a positive return on equity of 9.34%. The business’s revenue for the quarter was down 58.4% compared to the same quarter last year. During the same period last year, the business posted $0.14 earnings per share. As a group, research analysts expect that Acorda Therapeutics Inc will post -3.92 EPS for the current year.

ACOR has been the subject of several recent analyst reports. HC Wainwright set a $33.00 target price on shares of Acorda Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 23rd. BidaskClub upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, February 28th. Cantor Fitzgerald restated a “hold” rating and set a $20.00 price objective on shares of Acorda Therapeutics in a research report on Friday, February 15th. Oppenheimer restated a “hold” rating on shares of Acorda Therapeutics in a research report on Tuesday, March 19th. Finally, Zacks Investment Research upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 8th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. Acorda Therapeutics currently has an average rating of “Hold” and an average price target of $22.56.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/21/teacher-retirement-system-of-texas-acquires-shares-of-185143-acorda-therapeutics-inc-acor.html.

Acorda Therapeutics Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Story: How mutual funds make money

Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics Inc (NASDAQ:ACOR).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.